Written questions and answers

Written questions allow Members of Parliament to ask government ministers for information on the work, policy and activities of government departments.

Historical written answers can be found in Hansard.

Find the latest written questions and answers for the 2017-19 session below. We welcome your feedback on this service.

Show
by:
Find by:
Close

UIN

Unique Identifying Number – Every written question in the House of Commons has a UIN per Parliament. In the House of Lords each written questions has a UIN per parliamentary session.
Showing 1-20 out of 498
Results per page
Results per page 20 | 50 | 100
Expand all answers
Print selected
Q
(Brighton, Pavilion)
Asked on: 09 July 2018
Ministry of Defence
USA: Military Alliances
Commons
To ask the Secretary of State for Defence, with reference to the joint meeting held in Washington on 26 June 2018 to mark the 60th anniversary of the 1958 Agreement between the Government of the United Kingdom of Great Britain and Northern Ireland and the Government of the United States of America for Cooperation on the Uses of Atomic Energy for Mutual Defense Purposes, if he will publish the (a) agenda for that meeting, (b) list of attendees and their official affiliations, (c) presentations made at that meeting and (d) the decisions taken in relation to the future of that agreement.
A
Answered by: Gavin Williamson
Answered on: 13 July 2018

The event, hosted at the headquarters of the US Department of Energy, was not a formal meeting, but an occasion to highlight 60 years of cooperation as well as unveiling an exhibition showcasing the agreement. The event included speeches and panel discussions but was not intended as a decision-making forum and therefore there were no presentations or decisions taken at the event.

Copies of the event programme and a list of senior UK attendees will be placed in the Library of the House in due course.

Q
(Brighton, Pavilion)
Asked on: 13 July 2018
Department for Education
Commons
To ask the Secretary of State for Education, how many children were referred to children’s social services on more than one occasion in the same reporting year in each of the last five years in (a) England and (b) Brighton and Hove.
Q
(Brighton, Pavilion)
Asked on: 13 July 2018
Department for Education
Commons
To ask the Secretary of State for Education, how many children were referred to children’s social services on at least one occasion in consecutive reporting years in each of the last five years in (a) England and (b) Brighton and Hove.
Q
(Brighton, Pavilion)
Asked on: 13 July 2018
Department for Education
Commons
To ask the Secretary of State for Education, how his Department incentivises local authorities' children’s services to provide early help services that can prevent problems reaching crisis point.
Q
(Brighton, Pavilion)
Asked on: 04 July 2018
Department of Health and Social Care
Lyme Disease
Commons
To ask the Secretary of State for Health and Social Care, with reference to the report entitled Stakeholder experiences of the diagnosis of Lyme disease, A systematic review, published by Department of Health Reviews Facility in December 2017, what steps he has taken to improve the (a) diagnosis, (b) technology for and (c) testing of Lyme disease since the publication of that report.
A
Answered by: Caroline Dinenage
Answered on: 12 July 2018

The Department commissioned four independent separate systematic reviews of all relevant literature on the diagnosis, treatment, transmission and prevention of Lyme disease.

The four systematic reviews were completed and published in December 2017 which assessed the existing evidence. The Department is aware of the findings which are available to the public, the research community and all research funders.

We are investing over £1 billion a year in health research through the National Institute for Health Research (NIHR). The usual practice of the NIHR is not to ring-fence funds for expenditure on particular topics: research proposals in all areas compete for the funding available. The NIHR welcomes funding applications for research on Lyme disease including those that reflect the conclusions of the systematic reviews as part of its regular processes. All applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.

Q
(Brighton, Pavilion)
Asked on: 05 July 2018
Department for International Trade
UK Trade and Investment Defence and Security Organisation
Commons
To ask the Secretary of State for International Trade, what the Defence and Security Organisation core markets are for 2018-19; and if he will make a statement.
A
Answered by: Graham Stuart
Answered on: 12 July 2018

The Department for International Trade, Defence and Security Organisation has identified the following core markets for 2018-19 with defence and security opportunities:

Australia
Austria
Bahrain
Belgium
Canada
France
Germany
India
Indonesia
Italy (lead for Mediterranean Defence Network Defence includes Spain & Portugal)
Japan
Kuwait
Latin America (Columbia, Brazil, Chile, Peru, Panama, Argentina, Mexico)
Malaysia
New Zealand
Netherlands
North Africa (Algeria, Tunisia, Egypt)
Oman
Philippines
Poland (within Central European Network and including Czech Republic, Romania, Slovakia, Bulgaria)
Qatar
Saudi Arabia
Singapore
South Korea
Southern Africa (South Africa, Botswana, Mozambique, Angola)
Sweden (lead for Nordic Baltic Network including Finland, Norway, Denmark, Lithuania, Estonia, Latvia)
Switzerland
Thailand
Turkey
United Arab Emirates
United States of America

Q
(Brighton, Pavilion)
Asked on: 02 July 2018
Department for Transport
Govia Thameslink Railway: Tickets
Commons
To ask the Secretary of State for Transport, how much revenue his Department has received from Govia Thameslink Railway from first class ticket premiums on (a) Thameslink, (b) Great Northern, (c) Southern and (d) Gatwick Express services for each of the last three years.
A
Answered by: Joseph Johnson
Answered on: 11 July 2018

Govia Thameslink Railway does not report revenue to the Department at the level of detail requested. Total Passenger Revenue for the Govia Thameslink Railway franchise can be found on the Office of Rail and Road Data Portal at the following link: http://orr.gov.uk/rail/publications/reports/uk-rail-industry-financial-information. From this data, the total Passenger Income for 2016/17 (the latest year for which data is available) was £1.24 Billion.

Q
(Brighton, Pavilion)
Asked on: 04 July 2018
Department for Transport
Railways: Standards
Commons
To ask the Secretary of State for Transport, with reference to the letter of 28 June 2018 from the Minister of State for Transport to hon. Members on the declassification of first class trains on Thameslink and Great Northern Services, whether that policy applies to (a) Southern and (b) Gatwick Express services; and if he will make a statement.
A
Answered by: Joseph Johnson
Answered on: 11 July 2018

Govia Thameslink Railway (GTR) has declassified first class areas on peak time trains on the Thameslink and Great Northern routes of operation. As is usual industry practice, GTR will continue to declassify first class areas on Southern and Gatwick Express services in times of disruption which it did on Thursday 5 July. Also, on board staff are empowered to take such decisions on a service by service basis.

Q
(Brighton, Pavilion)
Asked on: 04 July 2018
Department of Health and Social Care
Naloxone
Commons
To ask the Secretary of State for Health and Social Care, if he will bring forward legislative proposals to enable the provision of new nasal forms of naloxone to help prevent deaths from opioid overdose; and if he will make a statement.
A
Answered by: Steve Brine
Answered on: 11 July 2018

Naloxone is a prescription-only medicine and it is on this basis that any new nasal naloxone products would be available when brought to the United Kingdom market. Under regulations that came into force in October 2015, people employed or engaged in the provision of drug treatment services can, as part of their role, supply naloxone that has been obtained by their drug service to others, as long as it is supplied for the purpose of being available to save life in an emergency. A prescription is not needed for the naloxone to be supplied in this way.

There has been no formal assessment of the decision of the European Medicines Agency to approve nasal forms of naloxone, however, officials from the Department, the Medicines and Healthcare products Regulatory Agency and Public Health England (PHE) continue to work together to identify the best available legislative option to enable nasal naloxone to be provided on the same basis as injectable naloxone.

Local authorities are responsible for commissioning drug treatment services and interventions to reduce drug-related harm, including naloxone, based on local need. PHE continues to provide advice and support to local authorities on expanding naloxone provision.

Grouped Questions: 160730
Q
(Brighton, Pavilion)
Asked on: 04 July 2018
Department of Health and Social Care
Naloxone
Commons
To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his policies of the approval by the European Medicines Agency of nasal forms of naloxone to prevent deaths from opioid overdose; what progress his Department has made on implementing the guidance published by his Department entitled Widening the availability of naloxone; and if he will make a statement.
A
Answered by: Steve Brine
Answered on: 11 July 2018

Naloxone is a prescription-only medicine and it is on this basis that any new nasal naloxone products would be available when brought to the United Kingdom market. Under regulations that came into force in October 2015, people employed or engaged in the provision of drug treatment services can, as part of their role, supply naloxone that has been obtained by their drug service to others, as long as it is supplied for the purpose of being available to save life in an emergency. A prescription is not needed for the naloxone to be supplied in this way.

There has been no formal assessment of the decision of the European Medicines Agency to approve nasal forms of naloxone, however, officials from the Department, the Medicines and Healthcare products Regulatory Agency and Public Health England (PHE) continue to work together to identify the best available legislative option to enable nasal naloxone to be provided on the same basis as injectable naloxone.

Local authorities are responsible for commissioning drug treatment services and interventions to reduce drug-related harm, including naloxone, based on local need. PHE continues to provide advice and support to local authorities on expanding naloxone provision.

Grouped Questions: 160729
Q
(Brighton, Pavilion)
Asked on: 11 July 2018
Department for Work and Pensions
Commons
To ask the Secretary of State for Work and Pensions, what the total monthly receipts to the public purse were from (a) the fee charged for applications to the Child Maintenance Service (CMS), (b) the collection fee for paying parents using the CMS Collect and Pay service, (c) the collection fee for receiving parents using the CMS Collect and Pay service and (d) enforcement fees levied on paying parents in each month since and including April 2016.
Q
(Brighton, Pavilion)
Asked on: 11 July 2018
Department for Work and Pensions
Commons
To ask the Secretary of State for Work and Pensions, what estimate she has made of receipts to the public purse from Child Maintenance Service charges in each year from 2020-21 up to and including 2025/26.
Q
(Brighton, Pavilion)
Asked on: 02 July 2018
Ministry of Housing, Communities and Local Government
Rented Housing: Energy Performance Certificates
Commons
To ask the Secretary of State for Housing, Communities and Local Government, pursuant to the Answer of 9 November 2017 to Question 151139 on Energy Performance Certificates, and the Answer of 15 June 2018 to Question 111244 on Energy Performance Certificates, if he will publish the conclusions reached on levels of compliance with Energy Performance Certificates for the rental sector during each calendar year from 2008-9 to 2016-17; and if he will make a statement.
A
Answered by: Kit Malthouse
Answered on: 10 July 2018

It is the responsibility of the person selling or renting a building to ensure that an Energy Performance Certificate (EPC) is made available. Data on the numbers of EPCs lodged is available at: https://www.gov.uk/government/statistical-data-sets/live-tables-on-energy-performance-of-buildings-certificates. This includes data on energy performance certificates lodged for the purposes of a private rental. However, the Government does not hold data about the number of buildings in the private rented sector for which an EPC should have been made available but has not been.

Q
(Brighton, Pavilion)
Asked on: 29 June 2018
Home Office
Cannabis: Medical Treatments
Commons
To ask the Secretary of State for the Home Department, what representations he has received from pharmaceutical companies on the use of medicinal cannabis in the last two years; and if he will publish the information his Department holds on the position of those companies on whether cannabis and cannabis-based medicinal products should be rescheduled under the Misuse of Drugs Regulations 2001.
A
Answered by: Mr Nick Hurd
Answered on: 09 July 2018

As I announced on 19 June, the Government is undertaking a two-phase review looking at the scheduling of cannabis. Part one of the review considered international evidence for the medicinal and therapeutic benefits of cannabis and cannabis based medicinal products. Professor Dame Sally Davies, who also serves as the Chief Medical Advisor to the Government and Chief Medical Officer for England, took this forward independently.

This part of the review is now complete and the report was published on 3 July. Also on 3 July, the Home Secretary commissioned the Advisory Council on the Misuse of Drugs (ACMD) to undertake part two of the Review. Supported by the Home Office and the Department of Health and Social Care, the Advisory Council on the Misuse of Drugs will consider the appropriate schedule for cannabis related products, based on the balance of harms and public health requirements. The ACMD will not reassess the evidence issued by Professor Dame Sally Davies.

I can confirm that my department has not received any representations from pharmaceutical companies on the use of medicinal cannabis in the last two years. In the last 12 months, the Home Office has discussed the potential use of Epidiolex as an alternative option for treatment with the manufacturer, GW Pharmaceuticals.

Given the Home Office’s role leading on regulatory governance it is not for the department to provide funding for multi-centre trials on the medicinal and therapeutic benefits of cannabis and cannabis-based products.

Grouped Questions: 158982 | 158983 | 158984 | 158985
Q
(Brighton, Pavilion)
Asked on: 29 June 2018
Home Office
Cannabis: Medical Treatments
Commons
To ask the Secretary of State for the Home Department, if he will make funding available for multi-centre trials on the medicinal and therapeutic benefits of (a) cannabis and (b) cannabis-based products.
A
Answered by: Mr Nick Hurd
Answered on: 09 July 2018

As I announced on 19 June, the Government is undertaking a two-phase review looking at the scheduling of cannabis. Part one of the review considered international evidence for the medicinal and therapeutic benefits of cannabis and cannabis based medicinal products. Professor Dame Sally Davies, who also serves as the Chief Medical Advisor to the Government and Chief Medical Officer for England, took this forward independently.

This part of the review is now complete and the report was published on 3 July. Also on 3 July, the Home Secretary commissioned the Advisory Council on the Misuse of Drugs (ACMD) to undertake part two of the Review. Supported by the Home Office and the Department of Health and Social Care, the Advisory Council on the Misuse of Drugs will consider the appropriate schedule for cannabis related products, based on the balance of harms and public health requirements. The ACMD will not reassess the evidence issued by Professor Dame Sally Davies.

I can confirm that my department has not received any representations from pharmaceutical companies on the use of medicinal cannabis in the last two years. In the last 12 months, the Home Office has discussed the potential use of Epidiolex as an alternative option for treatment with the manufacturer, GW Pharmaceuticals.

Given the Home Office’s role leading on regulatory governance it is not for the department to provide funding for multi-centre trials on the medicinal and therapeutic benefits of cannabis and cannabis-based products.

Grouped Questions: 158981 | 158983 | 158984 | 158985
Q
(Brighton, Pavilion)
Asked on: 29 June 2018
Home Office
Cannabis: Medical Treatments
Commons
To ask the Secretary of State for the Home Department, whether part one of the Government’s two-part review of the scheduling of cannabis will consider evidence from overseas, including Germany, of the medicinal and therapeutic benefits of cannabis and cannabis-based products.
A
Answered by: Mr Nick Hurd
Answered on: 09 July 2018

As I announced on 19 June, the Government is undertaking a two-phase review looking at the scheduling of cannabis. Part one of the review considered international evidence for the medicinal and therapeutic benefits of cannabis and cannabis based medicinal products. Professor Dame Sally Davies, who also serves as the Chief Medical Advisor to the Government and Chief Medical Officer for England, took this forward independently.

This part of the review is now complete and the report was published on 3 July. Also on 3 July, the Home Secretary commissioned the Advisory Council on the Misuse of Drugs (ACMD) to undertake part two of the Review. Supported by the Home Office and the Department of Health and Social Care, the Advisory Council on the Misuse of Drugs will consider the appropriate schedule for cannabis related products, based on the balance of harms and public health requirements. The ACMD will not reassess the evidence issued by Professor Dame Sally Davies.

I can confirm that my department has not received any representations from pharmaceutical companies on the use of medicinal cannabis in the last two years. In the last 12 months, the Home Office has discussed the potential use of Epidiolex as an alternative option for treatment with the manufacturer, GW Pharmaceuticals.

Given the Home Office’s role leading on regulatory governance it is not for the department to provide funding for multi-centre trials on the medicinal and therapeutic benefits of cannabis and cannabis-based products.

Grouped Questions: 158981 | 158982 | 158984 | 158985
Q
(Brighton, Pavilion)
Asked on: 29 June 2018
Home Office
Cannabis: Medical Treatments
Commons
To ask the Secretary of State for the Home Department, what input the Department of Health and Social Care will have into the Government’s two-part review of the scheduling of cannabis.
A
Answered by: Mr Nick Hurd
Answered on: 09 July 2018

As I announced on 19 June, the Government is undertaking a two-phase review looking at the scheduling of cannabis. Part one of the review considered international evidence for the medicinal and therapeutic benefits of cannabis and cannabis based medicinal products. Professor Dame Sally Davies, who also serves as the Chief Medical Advisor to the Government and Chief Medical Officer for England, took this forward independently.

This part of the review is now complete and the report was published on 3 July. Also on 3 July, the Home Secretary commissioned the Advisory Council on the Misuse of Drugs (ACMD) to undertake part two of the Review. Supported by the Home Office and the Department of Health and Social Care, the Advisory Council on the Misuse of Drugs will consider the appropriate schedule for cannabis related products, based on the balance of harms and public health requirements. The ACMD will not reassess the evidence issued by Professor Dame Sally Davies.

I can confirm that my department has not received any representations from pharmaceutical companies on the use of medicinal cannabis in the last two years. In the last 12 months, the Home Office has discussed the potential use of Epidiolex as an alternative option for treatment with the manufacturer, GW Pharmaceuticals.

Given the Home Office’s role leading on regulatory governance it is not for the department to provide funding for multi-centre trials on the medicinal and therapeutic benefits of cannabis and cannabis-based products.

Grouped Questions: 158981 | 158982 | 158983 | 158985
Q
(Brighton, Pavilion)
Asked on: 29 June 2018
Home Office
Cannabis: Medical Treatments
Commons
To ask the Secretary of State for the Home Department, what discussions his Department has had with representatives of the medicinal cannabis industry on the medicinal and therapeutic benefits of cannabis and cannabis-based medicinal products.
A
Answered by: Mr Nick Hurd
Answered on: 09 July 2018

As I announced on 19 June, the Government is undertaking a two-phase review looking at the scheduling of cannabis. Part one of the review considered international evidence for the medicinal and therapeutic benefits of cannabis and cannabis based medicinal products. Professor Dame Sally Davies, who also serves as the Chief Medical Advisor to the Government and Chief Medical Officer for England, took this forward independently.

This part of the review is now complete and the report was published on 3 July. Also on 3 July, the Home Secretary commissioned the Advisory Council on the Misuse of Drugs (ACMD) to undertake part two of the Review. Supported by the Home Office and the Department of Health and Social Care, the Advisory Council on the Misuse of Drugs will consider the appropriate schedule for cannabis related products, based on the balance of harms and public health requirements. The ACMD will not reassess the evidence issued by Professor Dame Sally Davies.

I can confirm that my department has not received any representations from pharmaceutical companies on the use of medicinal cannabis in the last two years. In the last 12 months, the Home Office has discussed the potential use of Epidiolex as an alternative option for treatment with the manufacturer, GW Pharmaceuticals.

Given the Home Office’s role leading on regulatory governance it is not for the department to provide funding for multi-centre trials on the medicinal and therapeutic benefits of cannabis and cannabis-based products.

Grouped Questions: 158981 | 158982 | 158983 | 158984
Q
(Brighton, Pavilion)
Asked on: 29 June 2018
Department of Health and Social Care
Cannabis: Medical Treatments
Commons
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with representatives of the medicinal cannabis industry on the medicinal and therapeutic benefits of (a) cannabis and (b) cannabis-based medicinal products.
A
Answered by: Steve Brine
Answered on: 09 July 2018

On 13 June 2018 the Parliamentary Under Secretary of State for Health (Lord O’Shaughnessy) and officials had an introductory meeting with GW Pharmaceuticals, which develops licensed medicines containing ingredients derived from cannabis, during which the benefits of that company’s medicines were discussed.

The Medicines and Healthcare products Regulatory Agency is responsible for the regulation of medicines in the United Kingdom and has provided advice and guidance, on request, to companies developing cannabis-based medicinal products, to support specific medical indications in relation to potential future marketing authorisation applications for new medicines.

Q
(Brighton, Pavilion)
[N]
Close

Named Day

'Named day' questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.

Asked on: 03 July 2018
Women and Equalities
Access to Elected Office for Disabled People Fund
Commons
To ask the Minister for Women and Equalities, pursuant to the Answers of 2 July 2018 to Questions 158205 and 158206, on Access to Elected Office Fund, how she plans to promote the existence of the £250,000 of new funding announced on 17 May 2018; and such planned promotion is expected to start.
A
Answered by: Victoria Atkins
Answered on: 09 July 2018

GEO is working on what the interim funding will cover and how it will be delivered. The Minister for Women and Equalities is keen that the delivery model and the communications around it help reinforce that political parties have the prime responsibility for supporting their disabled candidates. Further details will be announced in due course.

Expand all answers
Print selected
Showing 1-20 out of 498
Results per page
Results per page 20 | 50 | 100